
Beyond target expression: a modular framework to predict who benefits from antibody–drug conjugates
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQMG9OV29DRGxDdkxFTEFBM00zTko3OHctMlg4bVdidjNTNjVJOHlHVXY0aXZzOGF3ZklkejlXdy1Ea3RqU3BUTWVHODRlUzlFcDAxZmZzN3RlanVZeFNkM3pXUmVBc200ajBINGVIdFVVX3BGQkRJWHpIWlpVTk1hdk5EbUJzZmc5aWJJWlFIMmtobllERDZjbmxIazdDdERwY0tjeFgxNU04dWFJZ1dVVWNzdjNEWkp4bWxDcDNSd2E?oc=5" target="_blank">Beyond target expression: a modular framework to predict who benefits from antibody–drug conjugates</a>&nbsp;&nbsp;<font color="#6f6f6f">Bioengineer.org</font>
